<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825395</url>
  </required_header>
  <id_info>
    <org_study_id>04-0567</org_study_id>
    <nct_id>NCT01825395</nct_id>
  </id_info>
  <brief_title>Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome</brief_title>
  <acronym>3 4-DAP</acronym>
  <official_title>Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <brief_summary>
    <textblock>
      To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with&#xD;
      Lambert-Eaton myasthenic syndrome (LEMS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Lambert Eaton Myasthenic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3, 4-Diaminopyridine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older,&#xD;
&#xD;
          -  Diagnosed with LEMS,&#xD;
&#xD;
          -  If female, have a negative pregnancy test, and&#xD;
&#xD;
          -  If premenopausal, be willing to practice an effective form of birth control during the&#xD;
             study,&#xD;
&#xD;
          -  Tested and found by ECG not to have a prolonged QT syndrome,&#xD;
&#xD;
          -  Agree to have a second ECG at the time of peak drug effect,&#xD;
&#xD;
          -  Has understood and signed the Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is known to have a sensitivity to 3, 4-DAP,&#xD;
&#xD;
          -  Has a history of:&#xD;
&#xD;
               1. past or current seizures,&#xD;
&#xD;
               2. cardiac arrhythmia,&#xD;
&#xD;
               3. hepatic, renal or hematologic disease, or&#xD;
&#xD;
               4. severe asthma,&#xD;
&#xD;
          -  Is believed by the investigator to be unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven P Ringel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifampridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

